Novo Nordisk Leverages Implant Tech, Oral Pill, and Aggressive Buyback to Counter Eli Lilly’s Moment
The competitive heat from Eli Lilly is forcing Novo Nordisk onto the front foot. The US rival’s tirzepatide…
Novo Nordisk Broadens Arsenal with Implant Deal and MASH Approval as Buyback Sustains Momentum
Novo Nordisk is fighting back against Eli Lilly’s encroachment on multiple fronts — through a novel long-acting implant…
Novo Nordisk Battles Price War on Two Fronts: Implant Innovation and Medicare Access vs. Margin Eros
Novo Nordisk finds itself navigating a sharply divided landscape. On one side, a promising pipeline of next-generation treatments…
Novo Nordisk Leans on Buyback and Implant Deal as Price Wars Threaten Margins
Novo, Nordisk
Veröffentlicht: 08.07.2026 um 09:09 Uhr,
Redaktion boerse-global.de
Novo Nordisk…
Vivani Medical Enters into Agreement with Novo Nordisk to
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an…
Novo Nordisk Pushes on Two Fronts: Pill Adoption Surges as Implant Partnership Takes Shape
The Danish pharma giant is accelerating its assault on the obesity market from two distinct angles, pairing a…
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07,…